KRAS and neoplasm: In colorectal cancer, detecting and quantifying ctDNA by using common somatic mutations (i.e., APC, TP53, KRAS) and/or tumour epigenetic alterations (i.e., CDKN2A or RASSF2A methylation) has been demonstrated to be feasible and clinically relevant.